Divyaswathi Citla Sridhar: We Counsel Patients With Obesity About VTE Risk, But What Does Real-World Data Actually Show?
Divyaswathi Citla Sridhar, a pediatric hematologist and oncologist at Arkansas Children’s Hospital, shared a post on LinkedIn:
“We counsel patients with obesity about VTE risk—but what does real-world data actually show?
Our new study published in RPTH Journal analyzed >4 million females prescribed hormonal therapy and found:
• Higher VTE rates with several ethinyl-estradiol–containing therapies in obese users
• No significant VTE increase with progesterone-only therapy
Title: Venous thromboembolism in obese hormonal contraceptive users: a large national database study
Authors: Divyaswathi Citla-Sridhar, Madhvi Rajpurkar, Lakshmi Srivaths, Bethany Samuelson Bannow, Rachel P. Rosovsky, Nancy Sokkary.
Grateful to work with a fantastic group of collaborators: Madhvi Rajpurkar Lakshmi Srivaths Bethany Samuelson Bannow Rachel Rosovsky Nancy Sokkary & Foundation for Women & Girls With Blood Disorders.”
Learn more with Hemostasis Today.
-
Dec 16, 2025, 16:34Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
-
Dec 16, 2025, 16:22Leonardo Furtado Freitas Presents a Rare Hemorrhagic Hemangioblastoma Case
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
-
Dec 16, 2025, 13:58AHA Awards Shubham Misra Postdoc Grant for LVO Stroke Biomarker Research
-
Dec 16, 2025, 13:00ScholarGPS Ranks Emmanuel J. Favaloro No. 1 in the World for Hemostasis